These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 38233674)

  • 1. The impact and safety of encapsulated nanomaterials as a new alternative against carbapenem resistant bacteria. a systematic review.
    Abdallah OM; Shebl HR; Abdelsalam E; Mehrez SI
    World J Microbiol Biotechnol; 2024 Jan; 40(2):72. PubMed ID: 38233674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Repurposing to Fight Colistin and Carbapenem-Resistant Bacteria.
    Peyclit L; Baron SA; Rolain JM
    Front Cell Infect Microbiol; 2019; 9():193. PubMed ID: 31245302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens.
    Abdeta A; Bitew A; Fentaw S; Tsige E; Assefa D; Lejisa T; Kefyalew Y; Tigabu E; Evans M
    PLoS One; 2021; 16(12):e0256556. PubMed ID: 34855767
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent Antibiotics Active against Multidrug-Resistant Gram-Negative Bacteria.
    Otsuka Y
    Chem Pharm Bull (Tokyo); 2020; 68(3):182-190. PubMed ID: 32115524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Double-carbapenem therapy in the treatment of multidrug resistant Gram-negative bacterial infections: a systematic review and meta-analysis.
    Li YY; Wang J; Wang R; Cai Y
    BMC Infect Dis; 2020 Jun; 20(1):408. PubMed ID: 32527246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and
    Cruz-López F; Martínez-Meléndez A; Morfin-Otero R; Rodriguez-Noriega E; Maldonado-Garza HJ; Garza-González E
    Front Cell Infect Microbiol; 2022; 12():884365. PubMed ID: 35669117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
    Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
    Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-bacterial activity of inorganic nanomaterials and their antimicrobial peptide conjugates against resistant and non-resistant pathogens.
    Pardhi DM; Şen Karaman D; Timonen J; Wu W; Zhang Q; Satija S; Mehta M; Charbe N; McCarron PA; Tambuwala MM; Bakshi HA; Negi P; Aljabali AA; Dua K; Chellappan DK; Behera A; Pathak K; Watharkar RB; Rautio J; Rosenholm JM
    Int J Pharm; 2020 Aug; 586():119531. PubMed ID: 32540348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomaterials: The New Antimicrobial Magic Bullet.
    Ndayishimiye J; Kumeria T; Popat A; Falconer JR; Blaskovich MAT
    ACS Infect Dis; 2022 Apr; 8(4):693-712. PubMed ID: 35343231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative Treatment of Severe Gram-Negative Bacterial Infections by a New Class of Antibiotics Targeting LpxC.
    Lemaître N; Liang X; Najeeb J; Lee CJ; Titecat M; Leteurtre E; Simonet M; Toone EJ; Zhou P; Sebbane F
    mBio; 2017 Jul; 8(4):. PubMed ID: 28743813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine).
    Paul M; Carrara E; Retamar P; Tängdén T; Bitterman R; Bonomo RA; de Waele J; Daikos GL; Akova M; Harbarth S; Pulcini C; Garnacho-Montero J; Seme K; Tumbarello M; Lindemann PC; Gandra S; Yu Y; Bassetti M; Mouton JW; Tacconelli E; Rodríguez-Baño J
    Clin Microbiol Infect; 2022 Apr; 28(4):521-547. PubMed ID: 34923128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotic consumption versus the prevalence of carbapenem-resistant Gram-negative bacteria at a tertiary hospital in China from 2011 to 2017.
    Zhang D; Hu S; Sun J; Zhang L; Dong H; Feng W; Lei J; Dong Y
    J Infect Public Health; 2019; 12(2):195-199. PubMed ID: 30385238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of carbapenems versus alternative antimicrobials for treating complicated urinary tract infections caused by antimicrobial-resistant Gram-negative bacteria: protocol for a systematic review and meta-analysis.
    Maeda M; Hasegawa T; Noma H; Ota E
    BMJ Open; 2023 Apr; 13(4):e069166. PubMed ID: 37085310
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of Highly Resistant Gram-Negative Infections in the Intensive Care Unit in the Era of Novel Antibiotics.
    Clancy CJ; Nguyen MH
    Infect Dis Clin North Am; 2022 Dec; 36(4):791-823. PubMed ID: 36328637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Tamma PD; Hsu AJ
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative evaluation of microscan walkaway 96 plus ID/AST system and mikrolatest broth microdilution kit in assessing
    Singh RI; Bhatia M; Anusha KR; Singh V; Omar BJ; Gupta P
    Indian J Med Microbiol; 2019; 37(4):502-508. PubMed ID: 32436871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doripenem: an expected arrival in the treatment of infections caused by multidrug-resistant Gram-negative pathogens.
    Poulakou G; Giamarellou H
    Expert Opin Investig Drugs; 2008 May; 17(5):749-71. PubMed ID: 18447600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial treatment challenges in the era of carbapenem resistance.
    Peri AM; Doi Y; Potoski BA; Harris PNA; Paterson DL; Righi E
    Diagn Microbiol Infect Dis; 2019 Aug; 94(4):413-425. PubMed ID: 30905487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.